The molecular subtypes of breast cancer were as follows: 41 patients (50.6%) had luminal B breast cancer, 27 (33.3%) had HER2+/EP + breast cancer, 10 (12.3%) had TN breast cancer, 2 (2.5%) had luminal A breast cancer, and 1 (1.25%) luminal B/HER2+ breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.